{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:08:56Z","timestamp":1791389336488,"version":"4.3.3"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.bbrc.2013.11.104","type":"journal-article","created":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T18:48:56Z","timestamp":1386010136000},"page":"278-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes"],"prefix":"10.1016","volume":"443","author":[{"given":"Dasiel O.","family":"Borroto-Escuela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilber","family":"Romero-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Narvaez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Oflijan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi F.","family":"Agnati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell","family":"Fuxe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2013.11.104_b0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbrc.2010.09.110","article-title":"Dopamine D2 and 5-hydroxytryptamine 5-HT((2)A) receptors assemble into functionally interacting heteromers","volume":"401","author":"Borroto-Escuela","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2013.11.104_b0010","first-page":"1347","article-title":"Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors","volume":"2010","author":"Lukasiewicz","year":"1803","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2013.11.104_b0015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.brainresrev.2007.09.007","article-title":"Adaptive properties and heterogeneity of dopamine D(2) receptors \u2013 pharmacological implications","volume":"58","author":"Carlsson","year":"2008","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.bbrc.2013.11.104_b0020","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.neuropharm.2011.05.023","article-title":"Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors","volume":"61","author":"Albizu","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbrc.2013.11.104_b0025","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1021\/jm00388a032","article-title":"N-methyl derivatives of the 5-HT2 agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane","volume":"30","author":"Glennon","year":"1987","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2013.11.104_b0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00176847","article-title":"Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens","volume":"94","author":"Titeler","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbrc.2013.11.104_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1476-5381.1968.tb07943.x","article-title":"Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide","volume":"34","author":"Anden","year":"1968","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2013.11.104_b0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-009-1694-1","article-title":"The serotonin 5-HT(2A) receptor agonist TCB-2: a behavioral and neurophysiological analysis","volume":"212","author":"Fox","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbrc.2013.11.104_b0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/B978-0-12-391862-8.00015-6","article-title":"G protein-coupled receptor heterodimerization in the brain","volume":"521","author":"Borroto-Escuela","year":"2013","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bbrc.2013.11.104_b0050","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.bbrc.2010.12.083","article-title":"Dopamine D2 and D4 receptor heteromerization and its allosteric receptor\u2013receptor interactions","volume":"404","author":"Borroto-Escuela","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2013.11.104_b0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2144\/000113719","article-title":"Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum","volume":"51","author":"Trifilieff","year":"2011","journal-title":"Biotechniques"},{"key":"10.1016\/j.bbrc.2013.11.104_b0060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.biopsych.2011.09.012","article-title":"Fibroblast growth factor receptor 1\u20135-hydroxytryptamine 1A heteroreceptor complexes and their enhancement of hippocampal plasticity","volume":"71","author":"Borroto-Escuela","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbrc.2013.11.104_b0065","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1471-4892(01)00091-1","article-title":"Reporter-gene systems for the study of G-protein-coupled receptors","volume":"1","author":"Hill","year":"2001","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bbrc.2013.11.104_b0070","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1476-5381.2010.00779.x","article-title":"Insights into GPCR pharmacology from the measurement of changes in intracellular cyclic AMP; advantages and pitfalls of differing methodologies","volume":"161","author":"Hill","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2013.11.104_b0075","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/JMN:24:2:173","article-title":"Biochemical identification of the dopamine D2 receptor domains interacting with the adenosine A2A receptor","volume":"24","author":"Torvinen","year":"2004","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.bbrc.2013.11.104_b0080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0014-2999(96)00665-6","article-title":"Adenosine A2A receptors modulate the binding characteristics of dopamine D2 receptors in stably cotransfected fibroblast cells","volume":"316","author":"Dasgupta","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2013.11.104_b0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0891-0618(01)00133-8","article-title":"Relationships of 5-hydroxytryptamine immunoreactive terminal-like varicosities to 5-hydroxytryptamine-2A receptor-immunoreactive neuronal processes in the rat forebrain","volume":"22","author":"Jansson","year":"2001","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.bbrc.2013.11.104_b0090","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1073\/pnas.95.2.735","article-title":"5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites","volume":"95","author":"Jakab","year":"1998","journal-title":"Proc. Natl. Acad Sci. U.S.A."},{"key":"10.1016\/j.bbrc.2013.11.104_b0095","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1021\/jm060656o","article-title":"1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists","volume":"49","author":"Mclean","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2013.11.104_b0100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd1062","article-title":"Discovering risperidone: the LSD model of psychopathology","volume":"2","author":"Colpaert","year":"2003","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.bbrc.2013.11.104_b0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbrc.2013.11.104_b0110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbrc.2013.11.104_b0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/schbul\/2.1.19","article-title":"The dopamine hypothesis of schizophrenia: a review","volume":"2","author":"Meltzer","year":"1976","journal-title":"Schizophr. Bull."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X13020068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X13020068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T01:11:36Z","timestamp":1746061896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X13020068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0006291X13020068"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2013.11.104","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2013.11.104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}